Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Clin Invest ; 117(12): 3971-8, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18037991

RESUMEN

Maternal smoking during pregnancy is associated with a variety of adverse neonatal outcomes including altered reproductive performance. Herein we provide molecular evidence for a pathway involved in the elimination of the female germline due to prepregnancy and/or lactational exposure to polycyclic aromatic hydrocarbons (PAHs), environmental toxicants found in cigarette smoke. We show that ovaries of offspring born to mice exposed to PAHs contained only a third of the ovarian follicle pool compared with offspring of unexposed female mice. Activation of the cell death pathway in immature follicles of exposed females was mediated by the aryl hydrocarbon receptor (Ahr), as ovarian reserve was fully rescued by maternal cotreatment with the Ahr antagonist, resveratrol, or by inactivation of the Ahr gene. Furthermore, in response to PAHs, Ahr-mediated activation of the harakiri, BCL2 interacting protein (contains only BH3 domain), was necessary for execution of cell death. This pathway appeared to be conserved between mouse and human, as xenotransplanted human ovarian cortex exposed to PAHs responded by activation of the identical cell death cascade. Our data indicate that maternal exposure to PAHs prior to pregnancy and/or during lactation compromises ovarian reserve of female offspring, raising the concern about the transgenerational impact of maternal smoking on ovarian function in the human.


Asunto(s)
Proteínas Reguladoras de la Apoptosis/biosíntesis , Exposición Materna/efectos adversos , Neuropéptidos/biosíntesis , Folículo Ovárico/metabolismo , Hidrocarburos Policíclicos Aromáticos/toxicidad , Efectos Tardíos de la Exposición Prenatal/metabolismo , Fumar/efectos adversos , Contaminación por Humo de Tabaco/efectos adversos , Animales , Anticarcinógenos/farmacología , Muerte Celular/efectos de los fármacos , Femenino , Humanos , Folículo Ovárico/anomalías , Folículo Ovárico/fisiopatología , Folículo Ovárico/trasplante , Embarazo , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Efectos Tardíos de la Exposición Prenatal/tratamiento farmacológico , Efectos Tardíos de la Exposición Prenatal/fisiopatología , Receptores de Hidrocarburo de Aril/metabolismo , Resveratrol , Estilbenos/farmacología , Trasplante Heterólogo
2.
Toxicol Appl Pharmacol ; 207(2 Suppl): 544-9, 2005 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-15990135

RESUMEN

The two most promising practical applications of human stem cells are cellular replacement therapies in human disease and toxicological screening of candidate drug molecules. Both require a source of human stem cells that can be isolated, purified, expanded in number and differentiated into the cell type of choice in a controlled manner. Currently, uses of both embryonic and adult stem cells are investigated. While embryonic stem cells are pluripotent and can differentiate into any specialised cell type, their use requires establishment of embryonic stem cell lines using the inner cell mass of an early pre-implantation embryo. As the blastocyst is destroyed during the process, ethical issues need to be carefully considered. The use of embryonic stem cells is also limited by the difficulties in growing large numbers of the cells without inducing spontaneous differentiation, and the problems in controlling directed differentiation of the cells. The use of adult stem cells, typically derived from bone marrow, but also from other tissues, is ethically non-controversial but their differentiation potential is more limited than that of the embryonic stem cells. Since human cord blood, umbilical cord, placenta and amnion are normally discarded at birth, they provide an easily accessible alternative source of stem cells. We review the potential and current status of the use of adult stem cells derived from the placenta or umbilical cord in therapeutic and toxicological applications.


Asunto(s)
Placenta/citología , Células Madre/citología , Femenino , Sangre Fetal , Humanos , Medicina Regenerativa , Trasplante de Células Madre , Bancos de Tejidos
3.
FASEB J ; 19(7): 860-2, 2005 May.
Artículo en Inglés | MEDLINE | ID: mdl-15728664

RESUMEN

An age-dependent acceleration of apoptosis occurs in female germ cells (oocytes), and this requires communication between the oocyte and its surrounding somatic (cumulus) cells. Here we show in aged mice that ceramide is translocated from cumulus cells into the adjacent oocyte and induces germ cell apoptosis that can be prevented by sphingosine-1-phosphate. Trafficking of ceramide requires gap junction-dependent communication between the cumulus cells and the oocyte as well as intact lipid rafts. Further, the occurrence of the elevated incidence of apoptosis in oocytes of aged females is concomitant with an enhanced sensitivity of the oocyte to a spike in cytosolic ceramide levels, as well as increased bax mRNA and Bax protein levels. Thus, the force driving the age-related increase in female germ cell death is multifactorial, but changes in the intercellular trafficking of ceramide, along with hypersensitivity of oocytes to ceramide, are key factors in this process.


Asunto(s)
Envejecimiento/fisiología , Apoptosis/fisiología , Ceramidas/fisiología , Oocitos/fisiología , Animales , Apoptosis/efectos de los fármacos , Transporte Biológico , Comunicación Celular , Células Cultivadas , Ceramidas/análisis , Ceramidas/deficiencia , Ceramidas/farmacología , Citocromos c/metabolismo , Citosol/química , Femenino , Filipina/farmacología , Uniones Comunicantes/efectos de los fármacos , Uniones Comunicantes/fisiología , Ácido Glicirretínico/farmacología , Lisofosfolípidos/farmacología , Microdominios de Membrana/efectos de los fármacos , Microdominios de Membrana/fisiología , Ratones , Ratones Endogámicos ICR , Ratones Noqueados , Oocitos/química , Oocitos/ultraestructura , Folículo Ovárico/citología , Folículo Ovárico/fisiología , ARN Mensajero/análisis , Esfingosina/análogos & derivados , Esfingosina/farmacología , Proteína X Asociada a bcl-2/análisis , Proteína X Asociada a bcl-2/genética
4.
J Clin Endocrinol Metab ; 90(4): 1942-52, 2005 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15657370

RESUMEN

Heterozygous familial hypercholesterolemia (HeFH) is associated with elevated cholesterol levels and early-onset atherosclerosis. We assessed the efficacy and safety for up to 2 yr of pravastatin treatment in 19 girls and 11 boys (age range, 4.1-18.5 yr) with HeFH. Pravastatin was started at 10 mg/d, with a forced titration by 10 mg at 2, 4, 6, and 12 months until the target cholesterol level [< or =194 mg/dl (< or =5 mmol/liter)] was reached. By 2, 4, 6, 12, and 24 months of treatment, the total cholesterol levels had, respectively, decreased by 19, 20, 23, 27, and 26%, and the low-density lipoprotein cholesterol levels had decreased by 25, 27, 29, 33, and 32% compared with the dietary baseline values. Seventeen percent of patients had lipid deposits (carotid plaque, xanthomas, or corneal arcus) at baseline, and 27% had deposits at 1 yr. The side effects were mild, and no clinically significant elevations in alanine aminotransferase, creatine kinase, or creatinine were seen. Growth and pubertal maturation remained normal in all subjects. In conclusion, pravastatin treatment was safe and well tolerated. The efficacy in children with slight or moderate hypercholesterolemia was satisfactory, but in children with severe hypercholesterolemia, it was insufficient.


Asunto(s)
Hiperlipoproteinemia Tipo II/tratamiento farmacológico , Pravastatina/uso terapéutico , Tendón Calcáneo/diagnóstico por imagen , Adolescente , Hormona Adrenocorticotrópica/sangre , Arterias Carótidas/diagnóstico por imagen , Niño , Preescolar , Femenino , Estudios de Seguimiento , Crecimiento/efectos de los fármacos , Humanos , Hiperlipoproteinemia Tipo II/sangre , Hiperlipoproteinemia Tipo II/fisiopatología , Lípidos/sangre , Masculino , Cooperación del Paciente , Pravastatina/efectos adversos , Estudios Prospectivos , Desarrollo Sexual , Ultrasonografía
5.
Biol Reprod ; 72(1): 86-96, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15371271

RESUMEN

Deficiency of acid sphingomyelinase (ASM), an enzyme responsible for producing a pro-apoptotic second messenger ceramide, has previously been shown to promote the survival of fetal mouse oocytes in vivo and to protect oocytes from chemotherapy-induced apoptosis in vitro. Here we investigated the effects of ASM deficiency on testicular germ cell development and on the ability of germ cells to undergo apoptosis. At the age of 20 weeks, ASM knock-out (ASMKO) sperm concentrations were comparable with wild-type (WT) sperm concentrations, whereas sperm motility was seriously affected. ASMKO testes contained significantly elevated levels of sphingomyelin at the age of 8 weeks as detected by high-performance, thin-layer chromatography. Electron microscopy revealed that the testes started to accumulate pathological vesicles in Sertoli cells and in the interstitium at the age of 21 days. Irradiation of WT and ASMKO mice did not elevate intratesticular ceramide levels at 16 h after irradiation. In situ end labeling of apoptotic cells also showed a similar degree of cell death in both groups. After a 21-day recovery period, the numbers of primary spermatocytes and spermatogonia at G2 as well as spermatids were essentially the same in the WT and ASMKO testes, as detected by flow cytometry. In serum-free cultures both ASMKO and WT germ cells showed a significant increase in the level of ceramide, as well as massive apoptosis. In conclusion, ASM is required for maintenance of normal sphingomyelin levels in the testis and for normal sperm motility, but not for testicular ceramide production or for the ability of the germ cells to undergo apoptosis.


Asunto(s)
Apoptosis/fisiología , Espermatozoides/citología , Espermatozoides/fisiología , Esfingomielina Fosfodiesterasa/deficiencia , Animales , Muerte Celular/fisiología , Muerte Celular/efectos de la radiación , Células Cultivadas , Ceramidas/metabolismo , Medio de Cultivo Libre de Suero , Masculino , Ratones , Ratones Noqueados , Células de Sertoli/patología , Motilidad Espermática/fisiología , Espermatozoides/efectos de la radiación , Esfingomielina Fosfodiesterasa/genética , Esfingomielina Fosfodiesterasa/metabolismo , Esfingomielinas/metabolismo , Testículo/citología , Testículo/crecimiento & desarrollo , Testículo/efectos de la radiación
6.
Fertil Steril ; 82 Suppl 3: 1077-85, 2004 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-15474077

RESUMEN

OBJECTIVE: To investigate the effects of T, dihydrotestosterone (DHT), and 17beta-estradiol on human ovarian stromal tissue survival in culture and to identify steroids capable of inhibiting cell death in vitro. DESIGN: Prospective study. SETTING: Academic research setting. PATIENT(S): Thirty women, aged 18-38 years, undergoing gynecological operations for benign conditions and eight women, aged 27-36 years, undergoing IVF because of tubal obstruction or male factor infertility. INTERVENTION(S): Cultured tissue was exposed to T, DHT, 17beta-estradiol, or the anti-androgen casodex. MAIN OUTCOME MEASURE(S): Immunohistochemistry for androgen receptor (AR), Southern blot analysis of DNA fragmentation, histology, and in situ end labeling of apoptotic DNA. RESULT(S): Androgen receptors were detected in the ovarian stroma and granulosa cells of the primordial follicles, although they were more clearly seen in primary follicles and more advanced-stage follicles. Testosterone only marginally suppressed ovarian tissue apoptosis in vitro. DHT was more effective than T, whereas 17beta-estradiol had no notable effect on the viability of the tissue. The effects of androgens on the ovarian tissue may be mediated through ARs, since blocking the receptors with an AR antagonist reversed the suppressive effect of DHT. CONCLUSION(S): DHT may be useful for enhancing human ovarian tissue survival in vitro.


Asunto(s)
Dihidrotestosterona/farmacología , Estradiol/farmacología , Ovario/efectos de los fármacos , Ovario/fisiología , Testosterona/farmacología , Adulto , Antagonistas de Andrógenos/farmacología , Antagonistas de Receptores Androgénicos , Anilidas/farmacología , Apoptosis/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Técnicas de Cultivo , Femenino , Células de la Granulosa/efectos de los fármacos , Células de la Granulosa/fisiología , Humanos , Nitrilos , Ovario/metabolismo , Estudios Prospectivos , Receptores Androgénicos/metabolismo , Supervivencia Tisular/efectos de los fármacos , Compuestos de Tosilo
7.
Reprod Biol Endocrinol ; 1: 15, 2003 Feb 11.
Artículo en Inglés | MEDLINE | ID: mdl-12657159

RESUMEN

We recently demonstrated that caspase-3 is important for apoptosis during spontaneous involution of the corpus luteum (CL). These studies tested if prostaglandin F2alpha (PGF2alpha) or FAS regulated luteal regression, utilize a caspase-3 dependent pathway to execute luteal cell apoptosis, and if the two receptors work via independent or potentially shared intracellular signaling components/pathways to activate caspase-3. Wild-type (WT) or caspase-3 deficient female mice, 25-26 days old, were given 10 IU equine chorionic gonadotropin (eCG) intraperitoneally (IP) followed by 10 IU human chorionic gonadotropin (hCG) IP 46 h later to synchronize ovulation. The animals were then injected with IgG (2 micrograms, i.v.), the FAS-activating antibody Jo2 (2 micrograms, i.v.), or PGF2alpha (10 micrograms, i.p.) at 24 or 48 h post-ovulation. Ovaries from each group were collected 8 h later for assessment of active caspase-3 enzyme and apoptosis (measured by the TUNEL assay) in the CL. Regardless of genotype or treatment, CL in ovaries collected from mice injected 24 h after ovulation showed no evidence of active caspase-3 or apoptosis. However, PGF2alpha or Jo2 at 48 h post-ovulation and collected 8 h later induced caspase-3 activation in 13.2 +/- 1.8% and 13.7 +/- 2.2 % of the cells, respectively and resulted in 16.35 +/- 0.7% (PGF2alpha) and 14.3 PlusMinus; 2.5% TUNEL-positive cells when compared to 1.48 +/- 0.8% of cells CL in IgG treated controls. In contrast, CL in ovaries collected from caspase-3 deficient mice whether treated with PGF2alpha, Jo2, or control IgG at 48 h post-ovulation showed little evidence of active caspase-3 or apoptosis. CL of WT mice treated with Jo2 at 48 h post-ovulation had an 8-fold increase in the activity of caspase-8, an activator of caspase-3 that is coupled to the FAS death receptor. Somewhat unexpectedly, however, treatment of WT mice with PGF2alpha at 48 h post-ovulation resulted in a 22-fold increase in caspase-8 activity in the CL, despite the fact that the receptor for PGF2alpha has not been shown to be directly coupled to caspase-8 recruitment and activation. We hypothesize that PGF2alpha initiates luteolysis in vivo, at least in part, by increasing the bioactivity or bioavailability of cytokines, such as FasL and that multiple endocrine factors work in concert to activate caspase-3-driven apoptosis during luteolysis.


Asunto(s)
Apoptosis/efectos de los fármacos , Caspasas/fisiología , Cuerpo Lúteo/efectos de los fármacos , Dinoprost/farmacología , Luteólisis/efectos de los fármacos , Receptor fas/farmacología , Animales , Animales Congénicos , Apoptosis/fisiología , Caspasa 3 , Caspasa 8 , Caspasas/deficiencia , Caspasas/genética , Cuerpo Lúteo/citología , Cuerpo Lúteo/enzimología , Dinoprost/antagonistas & inhibidores , Dinoprost/inmunología , Activación Enzimática/efectos de los fármacos , Femenino , Luteólisis/fisiología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Progesterona/sangre , Transducción de Señal/efectos de los fármacos , Receptor fas/inmunología
8.
Endocrinology ; 143(4): 1495-501, 2002 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11897708

RESUMEN

Because caspase-3 is considered a primary executioner of apoptosis and has been implicated as a mediator of luteal regression, we hypothesized that corpora lutea (CL) derived from caspase-3 null mice would exhibit a delayed onset of apoptosis during luteal regression, when compared with CL derived from wild-type (WT) mice. To test this hypothesis, ovulation was synchronized in immature (postpartum d 24-27) WT and caspase-3-deficient female littermates by exogenous gonadotropins. Individual CL were isolated by manual dissection, 30 h after ovulation, and placed in organ culture dishes in the absence of serum and growth factors. At the time of isolation (0 h) and after 24, 48, and 72 h in culture, the CL were removed and assessed for the presence of processed (active) caspase-3 enzyme and for apoptosis by multiple criteria. There was no evidence of active caspase-3 enzyme or apoptosis in either WT or caspase-3-deficient CL before culture. However, CL derived from the WT mice exhibited a time-dependent increase in the level of active caspase-3 and apoptosis during culture. By comparison, CL derived from caspase-3-deficient mice, cultured in parallel, failed to exhibit any detectable active caspase-3 and showed attenuated rates of apoptosis. To extend these findings derived from ex vivo culture experiments, ovaries were collected from WT and caspase-3 null female littermates at 2, 4, or 6 d post ovulation, and the occurrence of apoptosis within the CL was analyzed. Whereas ovaries of WT mice had only residual luteal tissue at d 6 post ovulation, ovaries collected from caspase-3-deficient mice retained many CL, at d 6 post ovulation, that were similar in size to those observed in the early luteal phase of WT mice. Importantly, there was no dramatic increase in apoptosis in CL of caspase-3-deficient mice at any time point examined post ovulation, indicating that the involution process had indeed been delayed. In contrast, the levels of progesterone declined regardless of genotype. These data provide the first direct evidence that caspase-3 is functionally required for apoptosis to proceed normally during luteal regression. However, caspase-3 is not a direct mediator of the decrease in steroidogenesis associated with luteolysis.


Asunto(s)
Apoptosis/fisiología , Caspasas/fisiología , Cuerpo Lúteo/fisiología , Ovario/fisiología , Animales , Caspasa 3 , Caspasas/genética , Cuerpo Lúteo/citología , Cuerpo Lúteo/enzimología , ADN/biosíntesis , ADN/genética , ADN/aislamiento & purificación , Fragmentación del ADN/fisiología , Electroforesis en Gel de Poliacrilamida , Femenino , Inmunohistoquímica , Etiquetado Corte-Fin in Situ , Ratones , Ratones Noqueados , Técnicas de Cultivo de Órganos , Ovario/citología , Ovario/enzimología , Ovulación/fisiología , Progesterona/metabolismo , Ratas
9.
Endocrinology ; 143(2): 615-20, 2002 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-11796517

RESUMEN

We recently reported that a targeted disruption of the gene encoding the aromatic hydrocarbon receptor (AHR) in mice reduces fetal oocyte apoptosis, leading to a 2-fold increase in the number of primordial follicles endowed at birth. Although the identity of the natural ligand(s) for the AHR remains to be unequivocally established, these findings indicate that the level of AHR function is an important physiological determinant of how many oocytes will succumb to apoptosis during development of the fetal ovaries. Furthermore, the AHR is a well established receptor for polycyclic aromatic hydrocarbons (PAHs), a class of ubiquitous environmental chemicals known to cause the death of female germ cells in fetal life. Given the possibility that the AHR serves as a key mediator of fetal oocyte death under both physiological and pathological situations, this study was conducted to more fully examine the impact of PAH-AHR interaction on fetal ovarian germ cells. In addition, experiments were designed to begin identification of the mechanism(s) by which ligand activation of the AHR induces prenatal oocyte depletion after transplacental exposure of fetuses to PAHs in vivo. Embryonic d 13.5 murine fetal ovaries cultured in the presence of PAHs exhibited a high level of germ cell loss via apoptosis that was prevented by the selective AHR antagonist, alpha-napthoflavone (ANF). Immunohistochemical analysis revealed an accumulation of Bax protein in germ cells of fetal ovaries exposed to PAHs before the onset of apoptosis, whereas cotreatment with ANF inhibited the induction of Bax expression. The functional importance of increased Bax expression to the cytotoxic response was confirmed by findings that fetal ovarian germ cell loss caused by in utero exposure of wild-type female fetuses to PAHs was not observed in Bax-deficient female fetuses exposed in parallel. We conclude that a central role exists for the AHR in transducing the actions of PAHs in fetal ovarian germ cells, and that the proapoptotic Bcl-2 family member, Bax, is a required mediator of PAH-induced oocyte loss in female fetuses exposed to PAHs in utero.


Asunto(s)
Apoptosis/genética , Células Germinativas/fisiología , Ovario/fisiología , Proteínas Proto-Oncogénicas c-bcl-2/fisiología , Proteínas Proto-Oncogénicas/fisiología , Receptores de Hidrocarburo de Aril/genética , Factores de Transcripción/genética , 9,10-Dimetil-1,2-benzantraceno/farmacología , Animales , Células Cultivadas , Femenino , Feto , Células Germinativas/efectos de los fármacos , Ligandos , Ratones , Ratones Endogámicos C57BL , Oocitos/efectos de los fármacos , Ovario/citología , Ovario/embriología , Hidrocarburos Policíclicos Aromáticos/farmacología , Proteínas Proto-Oncogénicas/biosíntesis , Proteínas Proto-Oncogénicas/genética , Proteínas Proto-Oncogénicas c-bcl-2/biosíntesis , Proteínas Proto-Oncogénicas c-bcl-2/genética , Receptores de Hidrocarburo de Aril/biosíntesis , Proteína X Asociada a bcl-2
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA